Atovaquone/proguanil for malaria chemoprophylaxis – Could a difference in susceptibility during hepatic development explain the need to continue drug intake for 7 days post-exposure?

Thomas Hanscheid; Patricia Schlagenhauf; Martin P. Grobusch

doi:https://doi.org/10.1016/j.tmaid.2019.101527

Atovaquone/proguanil for malaria chemoprophylaxis – Could a difference in susceptibility during hepatic development explain the need to continue drug intake for 7 days post-exposure?

Thomas Hanscheid, Patricia Schlagenhauf, Martin P. Grobusch

Research output: Contribution to journal › Letter › Academic › peer-review

2 Citations (Scopus)

Original language	English
Article number	101527
Journal	Travel medicine and infectious disease
Volume	33
DOIs	https://doi.org/10.1016/j.tmaid.2019.101527
Publication status	Published - 1 Jan 2020

Access to Document

https://doi.org/10.1016/j.tmaid.2019.101527

Cite this

@article{e961f6b52ca745a49fb66b497396001f,

title = "Atovaquone/proguanil for malaria chemoprophylaxis – Could a difference in susceptibility during hepatic development explain the need to continue drug intake for 7 days post-exposure?",

author = "Thomas Hanscheid and Patricia Schlagenhauf and Grobusch, {Martin P.}",

year = "2020",

month = jan,

day = "1",

doi = "https://doi.org/10.1016/j.tmaid.2019.101527",

language = "English",

volume = "33",

journal = "Travel medicine and infectious disease",

issn = "1477-8939",

publisher = "Elsevier USA",